Long Chau and Viatris Vietnam Partner to Manage Dyslipidemia in the Community

Inside a pharmacy, people usually notice only the glass counter and the boxes of medicine. Few pay attention to the quieter work behind it: reading blood test results, checking LDL-C levels, and patiently explaining to a middle-aged man that high blood lipids do not hurt — until they cause a heart attack. Dyslipidemia is a disease of silence. Patients have no fever, no cough, no pain. They learn they carry it only after the body has already paid the price. According to the World Health Organization (WHO), cardiovascular disease is the leading cause of death worldwide, with about 17.9 million deaths each year. Dyslipidemia belongs to the group of modifiable risk factors — meaning it can be detected early and managed early, if someone reminds the patient at the right moment. That is the intersection the Long Chau pharmacy chain and Viatris Vietnam chose to work on: moving screening, counselling and follow-up for dyslipidemia out of hospital corridors and back into residential neighbourhoods. Long Chau is a retail pharmacy chain under FPT Retail, operating a network that reaches provinces and cities across Vietnam. Viatris Vietnam belongs to Viatris, a global pharmaceutical group created by the merger of Mylan and Upjohn — Pfizer's off-patent division — completed in November 2026. A retail system with wide coverage joining a drugmaker with a cardiovascular portfolio is a familiar model in many markets, but it remains relatively new in Vietnam. The key lies in the structure of the health system. Primary care facilities and hospitals carry enormous pressure, while most people at cardiovascular risk only come to hospital once symptoms appear. The gap between the first test and the routine follow-up visit is exactly where chronic disease progresses quietly. Pharmacies, which see residents more often than any other health facility, sit right inside that gap. The partnership is built around three groups: pharmacists at the pharmacy, cardiologists, and patients in the community. Pharmacists form the front line — the ones who ask, who record the numbers, who remind patients to return. Doctors form the professional line — the ones who confirm the diagnosis and set the treatment plan. And the community is where everything must happen continuously, not once. The starting point of the model has been reversed. Instead of waiting for patients to come to hospital, the programme brings testing and counselling to places people pass every day. In behavioural terms, this matters: the psychological cost of walking into a pharmacy is far lower than the cost of booking a specialist appointment. The pharmacist's role is also elevated. In the traditional model, pharmacists dispense against prescriptions. In the new model, they screen and follow up — a kind of memory for the health system, remembering each person's numbers across repeated measurements. This is the kind of data hospitals often lack, because patients move between places, see different doctors, and rarely carry complete paperwork. The next point is continuity of data. When a pharmacy chain shares a storage system, a person's test result in one district can still be retrieved after they move to another. For chronic disease, that is not a small convenience. It is the condition for a treatment plan not to break apart. For patients, the difference lies in the feeling of being followed. Someone reminded to retest after three months behaves differently from someone who takes a result sheet and files it in a drawer. Over many years making documentaries about community health, I have found that what changes human behaviour is not good advice, but a relationship long enough for the advice to be repeated. The model also raises questions about professional boundaries. To what extent may a pharmacy interpret lipid results? Who is responsible when a person is screened, receives a normal result, and is hospitalised three months later with a cardiovascular event? These questions cannot be answered by a commercial contract, but by practising regulations and training standards. For Viatris, the partnership follows a familiar pharmaceutical logic: widening access to treatment through distribution channels. That is not wrong. But it should be faced squarely: a community programme sponsored by a drug manufacturer always carries two parallel goals — raising awareness and expanding the market. The two do not exclude each other, but they should not be blended when effectiveness is assessed. Every community screening programme carries an implicit assumption: that early detection leads to early treatment, and early treatment leads to better outcomes. The logic holds in biomedical terms, but it often breaks in the middle. Clinical reality shows that adherence to dyslipidemia treatment is very low in many places. Patients take medication for a few months, feel nothing different, and stop on their own. They are not wrong in how they feel. They are simply reacting to a disease that sends no signal. The real value of a programme like this therefore lies in how many people come back for a fourth or fifth measurement — not in the number of tests on launch day. This is the part media often skips. The published figures tend to be the number of people screened, an easy and flattering metric. The harder and more meaningful one is the rate of continued follow-up after twelve months. If a programme stops at detection, it is like scoring a goal and leaving the pitch before the match ends. There is another issue: screening without a clear pathway into treatment creates a group of people who know they are at risk but do not know what to do next. That state can produce more anxiety than benefit. The question worth asking is therefore not how many people were screened, but how many of them had a concrete plan immediately after receiving their result. In preventive health, the most important work usually happens where nobody applauds: a reminder call, a number recorded on the right day, a pharmacist who remembers a patient's name. Applause nobody hears is still applause. The partnership between Long Chau and Viatris Vietnam has the potential to turn those small acts into a system. But potential is only a starting point. The real measure will come a year later, when someone counts how many people are still coming back.